FTSE 100 stocks have emerged as a favored investment choice among British investors, particularly as recent movements in the US stock market raise concerns about potential instability. With many American equities, especially in the technology sector, achieving all-time highs, experts are expressing caution regarding the possibility of a market correction or even a more severe downturn.
Historically, the FTSE 100 and US indices like the S&P 500 feature notable differences in sector composition. While the latter leans heavily towards technology, the FTSE 100 demonstrates greater diversification across typically defensive sectors such as healthcare, finance, and energy. This diversified structure has helped the UK index exhibit lower volatility levels.
However, during periods of significant market turmoil, the FTSE 100 does show vulnerability to sharp declines. For example, in 2020, both the FTSE 100 and the S&P 500 plunged by approximately 30% within a few weeks. Similarly, during the 2008 financial crisis and the dotcom crash of 2000-2002, both indices suffered around 50% losses.
Interestingly, the correlation between UK and US stocks tends to fluctuate during milder market corrections. For instance, in the inflation-driven correction of 2022, the FTSE 100 showed resilience, delivering flat performance while the S&P 500 experienced a 20% decline. The more diverse makeup of the FTSE 100 often results in lower volatility during these periods, with its robust composition helping to protect investor wealth. Additionally, as a significant portion of FTSE 100 earnings derives from overseas, a weakening pound can serve as a beneficial factor.
As speculation grows regarding a potential US market correction, investors are considering defensive positions within the FTSE 100. Experts suggest that large-cap healthcare firms such as AstraZeneca may be particularly appealing. The company boasts a strong development pipeline, positioning it well in the competitive cancer pharmaceuticals sector, while its existing products continue to deliver impressive double-digit growth.
AstraZeneca’s recent announcement of a $50 billion multi-year investment program to bolster its research and development and manufacturing capabilities could further enhance its long-term growth prospects. Nonetheless, investors should remain cautious, recognizing that no investment is devoid of risk. AstraZeneca faces challenges, such as a potential patent cliff where numerous blockbuster drugs could fall prey to generic competition. While promising new treatments may mitigate this issue, the drug development process is notoriously complex and costly, with numerous candidates failing to secure market approval.
In this climate of uncertainty surrounding the US stock market, exploring resilient businesses within the FTSE 100, like AstraZeneca, offers a viable opportunity for investors seeking to safeguard their portfolios.
